NetworkNewsWire Editorial Coverage:
The cannabinoid-based pharmaceutical market is rapidly expanding,
driving increased demand for a reliable flow of high-purity
cannabinoids. With a market that’s expected to grow from $2 billion
in 2020 to $50 billion in only nine years, according to
Statista (http://nnw.fm/3Uta4), biotechnology companies are
increasingly focused on the development of proprietary systems and
procedures to drive research and production of cannabinoid
pharmaceuticals. One of the leading companies in this sector is
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
(IMLFF
Profile), which has created
proprietary systems for bioinformatics and biosynthesis
manufacturing of pharmaceutical-grade cannabinoids. Axim
Biotechnologies, Inc. (OTCQB: AXIM) is taking a broader
approach as the creator of innovative systems for the research,
development and manufacture of new products in the pharmaceutical,
nutraceuticals, phytoplant and botanical fields. These companies
rely on bioinformatics tools to identify cannabinoids for medical
applications; another industry participant in this regard is
Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX),
which focuses on the development of personalized diagnostic and
bioinformatics tools. Aphria, Inc. (TSX: APH) (OTCQB:
APHQF), on the other hand, leverages the capabilities of
its proprietary systems to produce agriculturally grown medical
cannabis. Primarily focused on the development of modified and
reduced-risk tobacco products aimed at reducing the harm caused by
smoking, 22nd Century Group, Inc. (NYSE: XXII) is
also gaining ground in the cannabinoid market by successfully
creating industrial hemp plants that contain zero
tetrahydrocannabinol (THC).
These are just some of the biotechs that have recognized the
benefits of creating proprietary systems for new product
development. These systems provide them with increased control over
outcomes in their drive to create product of consistently high
purity. This is critical in the emerging cannabinoid drug sector,
where the Food and Drug Administration (FDA) has major concerns
regarding the consistency of drugs and products manufactured from
agricultural cannabis. Any biotech in this sector striving for
approval from the FDA must ensure that its products are able to
survive rigorous pharmaceutical testing and manufacturing
standards.
InMed
Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) is the
standout company in the field of pharmaceutical-grade cannabinoid
biosynthesis. By using its proprietary systems and methods, InMed
has developed the first bio-identical cannabinoid that has
undergone formulation and preclinical testing. InMed will use its
proprietary systems to develop other cannabinoid-based drugs,
leveraging its technology to ensure enhanced consistency in
production, purity, quality and structural integrity, all of which
greatly increase the likelihood of gaining FDA approval for its
candidates.
Using computer-based algorithms and proprietary bioinformatics
to identify active cannabinoid combinations for the treatment of
several diseases in dermatology, ocular disease, pain and other
conditions, the company has the capability to advance drug
candidates through formulation, preclinical and clinical
testing.
InMed’s biosynthesis platform has several other advantages over
agriculture-based production methods, including extensive cost
savings resulting from not having to contend with the
grow-harvest-extract-purify cycle necessary when using cannabis
crops. Additionally, InMed’s biosynthesis process can produce all
of the 90+ cannabinoids naturally found in cannabis, enabling the
company to avoid the harmful chemicals that are used in the
cannabis growing process and offering an easier way to scale-up
from the laboratory to full production.
The company’s preclinical development pipeline includes INM-750
for the treatment of epidermolysis bullosa (EB), an orphan
pediatric disease with no currently approved therapy. The potential
global market revenues for this drug are estimated at $1 billion.
INM-085, a second drug in development, is being studied as a
treatment option for glaucoma, with its global market value of over
$5 billion. More than three million Americans are estimated to be
living with glaucoma, and over 120,000 have been blinded by this
condition (http://nnw.fm/Of680).
The company has streamlined its proprietary systems, enabling it
to create bio-identical cannabinoids in the controlled setting of a
laboratory, and it is currently working on scaling up its
manufacturing capability. Once at commercial scale, the company
will be uniquely positioned to maximize its potential by assisting
other companies with cannabinoid-based drug development programs.
The company recently filed a provisional patent for biosynthesis of
cannabinoids. Once converted into an International Patent
Cooperation Treaty (PCT) application, InMed will look to pursue key
jurisdictions on an international scale (http://nnw.fm/WJ8zY).
Another company that is actively engaged in cannabinoid research
and development is Axim Biotechnologies
(OTCQB: AXIM). Based in the Netherlands, the
company is conducting research into a patented cannabinoid delivery
system to treat multiple sclerosis (MS) patients suffering from
pain and spasticity. Axim’s research and testing is conducted in
compliance with the strict guidelines of the FDA and European
Medicines Agency (EMA). In a recent development, on October 5,
2017, Axim was granted a patent for a cannabinoid ophthalmic
solution developed for the treatment of glaucoma and
conjunctivitis.
Cannabics Pharmaceuticals (OTCQB:
CNBX) provides diagnostic tools and bioinformatics to
support practitioners and patients. Also engaged in scientific and
clinical research through its subsidiary, Grin Ultra, the company
is developing cannabinoid-based medicine for cancer patients,
examining efficacy through in-vitro studies and clinical trials.
Cannabics is currently studying the effect of its proprietary
cannabis capsules on weight and appetite loss in cancer patients.
The company recently filed national phase patent applications for
its proprietary cannabis-based cancer cell screening technology in
the United States, Canada, Europe, Australia, China, India and
Brazil.
As a global leader in the production of medical cannabis,
Aphria (TSX: APH) (OTCQB: APHQF)
has a strong commitment to the production of high-quality, pure and
safe cannabis. The company is leveraging a controlled growth system
in which cannabis is cultivated only in the most natural conditions
available in order to offer safe and consistent products. With
different formulations in development, ranging from capsules to
oral solutions and vaporizers, Aphria also provides a portal for
both patients and health professionals to order their products. A
team of experts is also available to answer any patient questions
on issues relating to the use of cannabis in medical treatments. In
June 2017, Aphria was granted a license by Health Canada to extend
its cannabis production space by 57,000 square feet.
While its main focus is on regulating the nicotine levels in
tobacco plants and producing very low nicotine tobacco as an aid to
stop smoking, 22nd Century Group (NYSE:
XXII), with its proprietary genetic engineering technology
and expertise in plant breeding, is also an active player on the
cannabinoid manufacturing market. Via wholly-owned subsidiary
Botanical Genetics, LLC, the company has successfully created a
type of industrial hemp that is completely THC-free. This is set to
revolutionize the hemp industry by virtually guaranteeing a larger
output, as, under current U.S. federal laws, any hemp plants with a
THC concentration above 0.3 percent need to be destroyed. 22nd
Century Group is also continuing research into the development of
next-generation industrial hemp that will contain optimal levels of
medically-relevant cannabinoids, as well as the creation of hemp
varieties adapted to various climates around the world. The company
has just ended its first industrial hemp field trials with the
University of Virginia, a program that it plans to continue
throughout 2018 with its zero-THC plants.
By using proprietary technology and systems, leading
biotechnology companies in the field are not only spurring their
own growth and development, but also spearheading a revolutionary
approach to the production of pharmaceutical-grade cannabinoids and
industrial hemp. These efforts will ultimately impact the entire
industry and create growth opportunities for other cannabis
companies, as well.
For more information on InMed Pharmaceuticals, please visit:
InMed
Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
CNBX Pharmaceuticals (PK) (USOTC:CNBX)
Historical Stock Chart
From Dec 2024 to Jan 2025
CNBX Pharmaceuticals (PK) (USOTC:CNBX)
Historical Stock Chart
From Jan 2024 to Jan 2025
